Vevorisertib

DB21481InvestigationalSmall molecule

Vevorisertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Vevorisertib is a serine/threonine kinase inhibitor. Vevorisertib is under investigation in clinical... Vevorisertib is under investigation in clinical trial NCT02761694 (Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)).

Mechanism: Pharmacologically active on RAC-alpha serine/threonine-protein kinase, RAC-beta serine/threonine-protein kinase, and RAC-gamma serine/threonine-protein kinase
Curator reviewed
Formula / weight: C₃₅H₃₈N₈O · 586.744 g/mol (avg)

Resolves to

Compound

UNIIV6SX910Y31CAS1416775-46-6ChEMBLCHEMBL4802156ChEBI758478PubChem71138858

Structure

InChIKeyNZDSLYATTDIDPH-UHFFFAOYSA-NSMILESCN(C1CCN(CC1)C1=CC(=CC=C1)C1=CC=C2N=C(N(C2=N1)C1=CC=C(C=C1)C1(N)CCC1)C1=C(N)N=CC=C1)C(C)=O

Targets

P31749AKT1P31751AKT2Q9Y243AKT3

What you can answer from here — as of October 11, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vevorisertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account